Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Gross Profit (2016 - 2025)

Historic Gross Profit for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $75.6 million.

  • Adma Biologics' Gross Profit rose 2676.38% to $75.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.3 million, marking a year-over-year increase of 4269.86%. This contributed to the annual value of $219.6 million for FY2024, which is 14684.96% up from last year.
  • As of Q3 2025, Adma Biologics' Gross Profit stood at $75.6 million, which was up 2676.38% from $67.2 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Gross Profit peaked at $75.6 million during Q3 2025, and registered a low of -$1.7 million during Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $16.7 million (2023), whereas its average is $28.9 million.
  • In the last 5 years, Adma Biologics' Gross Profit crashed by 11450.19% in 2021 and then soared by 240602.49% in 2022.
  • Over the past 5 years, Adma Biologics' Gross Profit (Quarter) stood at $3.5 million in 2021, then soared by 303.76% to $14.2 million in 2022, then surged by 119.27% to $31.1 million in 2023, then soared by 103.73% to $63.3 million in 2024, then increased by 19.41% to $75.6 million in 2025.
  • Its Gross Profit was $75.6 million in Q3 2025, compared to $67.2 million in Q2 2025 and $61.1 million in Q1 2025.